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blo, provides better cosmosie and decreased morbidity for pediatric cardiac 
eurgory, This report reviews a 16 year experience with ASD repair through a 
right sided, minimally tnvaslvo thorncotomy (MIT). 
MofhoCs: From 4/81 through 3/07, 85 pts underwent MIT repair of ASD: 
80 pts had secundum ASD. 1 had scimitar syndrome, 1 had sinus vonoeus 
dof(~t end 3 ttsd osti.m primLtm defects. This technique has boon used 
excluelvely for ASD wpnlr since 1995, The mean ego w~e 83 ym (range 
1-41), A 5=9 em long akin Incision wee made In the right Ink.mammary akin 
fold, entering the chest through the 4th Intewostel sp~co, All pt, underwent 
ascending aorlle eannulstlon nd bleavat venoue eennuleflon, with et~ndard 
porfg~lon ~nd moderato hypothorml~ (30-32 °G), ~evenly.flve pts (88%) 
weelved ~ntegr~de srdloplogt~, 9 pts 111%) underwent (ibrlllatory arwst, 
and t pt (1%) with ~clmlfnr syndrome had hypothormte lwulatery ~rw,l, 
The cro~ cl~mp time wee ~0 :t 1~ min (mann ;I; ~D) and the bypass time 
w~s 38 ~ 18 rain, 
R~q~/t~: Th0w warn no hospital de~ths, neuwloglc complications or 
wound Inf~tlons, Operative espesuw was excellent in all pts and ¢onvor, ion 
fo sfowofomy was net wgeiwd, The mann poetepemllvo hospital etay was 
4,2 .~, 1,4 days, Late follow.up wvealed an excellent cosmetic resell, with 
normal bwast and chest well development In oveq/pt, 
Coneluslon,~: This 18 yr e~(portonce demonstrates the uniform safety and 
reprod(tqlblltty of a MIT approach for ASD repair, This technique offers a 
superior co,matte ms[tit w!th limited mo~tdily and a ,'~ero poment operative 
mortality Minimally l~'~ve~tw thotacotomv le the profaned approach for ASD 
wp~ir ~nd is tho benchmark agnlnst which oathetor b~sed device ~losuro 
mu~t be compared 
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~ L o n g  Term Surgery for  Out©ome of Anomalous 
Origin of the Left Coronary Artery From the 
Pulmonary Artery: A Twenty-Four Year Experience 
M, Ninon, J.L. Myers, T.H, "P~cy, R D, Slewors, DIW~ion of C~rdlofhomcic 
Su~ry  ,qnd CnrdlofPgy, ChlldrOn,~ Hospital of Plftsbi~rgft, Pittsburgh, 
F~nnsylvant~, USA 
Intro~¢flon: Few long term data of the results of eurgical management of 
anomalous origin of the loft coronary artery from the pulmonary arfoq/nw 
available in the Iltomtuw, 
Mefhc,('h3: Thirty four patt0nl~ with ~ loft main coronary artery arising from 
the pulmonary artery es an Isolated lesion wore oporsted on between 1973 
and 1997, Ages ranged from 2 woek~ to 9 years, Twenty seven patients (79%,) 
undorwunt imptnnhuiun o~ t,",,~ cft main :9~'~,,')0 am'%, f'~to the ~scon~i'~g 
aorta and 7 patients (21%) had a Takoucht procedure. 
Results: Follow.up ranged from 2 months to 24 years, Five of the thirty 
four patients died (mortality 14.7%). Four of the five deaths occurred before 
the availability of assist device systems, with only one death in the last 
14 y~ars. Of 29 suwivors, 25 (86%) have improved NYHA class on long 
term follow-up. Throe of four patients with poor results and a worse NYHA 
class h~d undergone a Takouchi procedure. All patients wore followed by 
echocardlography. Left ventricular function improved to near normal levels 
in 25 patients within six months of repair. Mitral incompetence was seen 
preoperatively tn 26 patients, and recovewd within six months in all but one 
survivor, Postoperative mechanical support has been used for loft ventricular 
failure in four patients, with throe survivors. 
Conclusions: 1, There is excellent long term functional outcome from 
direct aortocoronary connection for this condition. 2. Takeuchi proceduv,.; 
has a high incidence of late supravatvar pulmonary stenosis. 3. Mechanical 
support in the early postoperative period could avoid mortality from left 
vrmtdcular failure. 4, Mitral incompetence and loft ventricular function recover 
rapidly after aorta-coronary connection. 
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~ Ventrlcular Septal Defect Patch FenestraUon In 
Repair of Tetralogy of  Fallot With Diminutive 
Pulmonary Arteries 
B.A. Love, P, Lang. R.A. Jonas, J.E. Lock. Children's Hospital, Boston. 
Massachuse~s, USA 
Background: Repair of tetralogy of Fallot (TOF) with diminutive pulmonary 
arteries (PAs) can lead to suprasystemic right ventricular pressure (RVp), 
low cardiac output and death, Staged repair with ventricular septal defect 
(VSD) patch fenestration may prevent po.~t- operative demise, promote PA 
growth and allow for subsequent fenestration closure. The results of such an 
approach are unreported. 
Methods: Data were examined retrospectively for all patients with TOF 
who had a fenestrated VSD patch at our institution. 
Results: Between 1/85 and 6/97, 24 patients undergoing repair of TOF had 
fenestration of the VSD patch - 13 at initial bypass and 11 immediately post 
bypass for suprasystemic RVp. Median age 6.2 yrs 11-30). Median Nakata 
index 101 mm~Im ~ (51-180). Thore wow 2 eedy doath~, I fwm low c~rdinc 
oLttpul end 1 fwm e mtsdiwctod RV-PA conduit, Postoperatively. 2 patients 
had, 2/3 systemic RVp, while 20 had near.systemic RVp, Median artod.I sat- 
urntlon wee 90% (80-98), No gallant had oxcoesivo loft to right shunt. Mean 
follow up was 43 :t 41 me. The fenestration clos~l spontaneously in 7, was 
closed eS pan of a subsequent operation in 3, and with a twnscothefor double 
umTomlla device in 4, In B, the fenestration Is open imP/Ion aubgwup follow up 
4 me (0.-22)), Thew was nee late (sudden) death. Since VSD surge W, IB o! 
PP qurvlvnm had PA dilations and 6 hod wuperatlons (conduit (Jhang~ 2, uni. 
foceltz,'ttlon 2, PA pigsty 1, wstdu,t patch m~rgln VSD 1), At latest follow tip, 
the RV/L,V proe~,w ie 0,B t 0,2 and the arlonel I~atumtion t~ ~)5% (86..100), 
Conclusions: The data suggest that ptanned lonQstwtien of the VSD 
patch In wpstr of TOF with diminutive pulmonaq/salaries may t~ benof~i~L 
In many, the VSD will either cloeo spont~neouelv or can I~, c!osod in the 
e~th01ori~ation l~b, 
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~ T h e  Risk Pa©tofs Fontan.type Current  of Prectdures  
and the SlretQgV of  Palliation In Fontan Cand!da~s 
M Aoki, Y. Iraqi, Y T~kanashi, K Sea, M Torada, 11: Shin'oka, M. Ko~do. 
J, Ohio, Tokyo H,C)men~ ,~hc~f Col/ego, Tok~o, Japan 
D~lckgwimd: We h~ve boon extending the indication Of Fontan,typo prOcO- 
dqws iF) to thOSe who have pulmonary allery (PA) distortion, atnoventriculaf 
(AV) valve regurgitatirm, anomalous venous return, or suprm~ntncular (SV) 
ta(;:hy.~n'hythmia by additional simultaneous urgical intervonhons. The CUr, 
rent ask f,,tctors for F wow evaluated 
Me,'hOd~: Records of ~ ,,ft ~nsocutivo patients who had F tar venous 
anomalies at our unit between 1985 and 1996 wow wviewed Preoperative 
risk factors for hospital deaths (HD, 23 eases, 7.5%) were analyzed using 
stOpwiso logistic regwssion, The appendage.~o.PA direct anastomosis with 
oblique partition of the amum was the standard proceduw, and extonswe 
PA angioplasty (85 eases), AV valve plasty 1148), surgtcal ablation and AV 
node modification 141), cavopulmonary anastomosis (99), and co.ection of 
anomalous pulmonary venous mtum (21) wore simultaneously podormed 
when nocessmy. 
Results: Lower p.lmnnary bleed flew (Qp). laiger vontncutar end-dias- 
tolic volume (VEDV), presence of anomalous I:ulmormty venous return. 
and longer cardiopulmonary bypass time were identified as signihcant (p -: 
0.05) n.~k factors. PA dietortion, AV vah,,e regurgitation. SV tachyarrhythmla. 
anomalous systemic venous return, pulmonary vascular WSlstance (0.26 to 
4.4 units), PA index (175 to 1040), PA pressure (5 to 36 mmHg), ventncular 
oloclion fraction (0.36 to 0.76), age (1.2 to 32 years) did not have significant 
impact on HD within the ranges. The regression equation showed a consis- 
tent decrease in HD with an increase in Qp even with an expected increase 
in VEDV by the increase in Qp taken into account. 
Conclusions: PA di'qortion. AV valv~ regurgitation, anomalous systemic 
venous relum, aiid S~ tachyarrhythml~ are surgically correctable, and there- 
tore are not the nsk factors. As palliation for F, correction el PV anomaly. 
and a shunt that gives good Qp is important considenng development of pul. 
monary vascular bed in F candidates with decreased pulmonary blood flow, 
and early F is recommended before excessive increase in VEDV occurs with 
deterioration of ventncular function. 
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~ Complet ion Fontan Without the Use of  
Cardiopulmonary Bypass 
V.K.H, Tam. Atlanta, Georgia. USA 
Direct cavopulmonary connection using an exfracardiac onduit has the- 
erotical advantages in the management of children with single venlrieles. 
Completion Fortran using an extracardiac conduit may be accomplished 
without cardiopulmonary bypass (CPB). Experience with the first 15 consec- 
utive patients is reported. From January 1995 to July 1997, 15 patienls had 
an extracardiac IVC to pulmonary artery conduit constructed without the use 
of CPB. 11 of these 15 patients had hypoplastic left heart syndrome whilethe 
remaining had tricuspid atresia. Average age was 24 months, tram 18-34 
months. Average weight was 11 kg, from 8.6-12.4 k 9. Risk factors include. 
elevated pulmonary vascular resistance in one patient with hypoplastie left 
pulmonary artery, at least moderate AV valve regurgitation in 3 patients. An 
IVC to atrial shunt was dsnd during construction of the cavopulmonary con- 
nection. A s~ngle 4-mm fenestration was used. Postoperatively, there were no 
mortalities. One patient with hypoplastic left head syndrome and moderate 
tncuspid valve regurgitation required resuscitation for ventricular dysrhyth- 
mia. Complications in others include one mediastinitis, and superficial wound 
infection in a second. Pleural effusions persisted in 2 of 15 patients two weeks 
after surgery, Excluding the one patient who had digoxin related ventricular 
dysrhythmia, the average ICU stay was 3 days (1-6); length of hospital 
stay was 13 days (4-38); average ventilator hours were 14. hours following 
JACC Febnmn I~FJX AF!.~TRA('I'.~ (~d I¢~IA 
surgery (1-72), Them has been no late death, In Conclusion, com~tetion 
Fonten using an extmcardtac conduit w~thout CPB may be achievE~l with 
gratifying results, In the last 7 patients the Itv~mg~ rmspitel ength of stay 
was 7 d~y~ with an ICU stay ot 3, Any advnntago over mere conventmnal 
methods using CPB remains 1o be proven, 
[ J •  Advances Antithrombotlc Therapies for In 
ST-Segment Elevation Myocardial Infarction 
Tuesday, March 31, 1998, 10:30 a,m,-Noon 
Georgia World Congress Cenler, Lecture Hall g 
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~ Ab¢ lx lmab ( f lNPro)  Potm~llMtm Thmmboly=!~ In ST 
Ekn~t lon  Myocardial Infan,'tion: Rtmu,'t= o1TIMI t4  
EM, An~,  R,P. ~ano.  C.H ~ ,  M G i~,  AJJ, Adgey, 
M Ghall, P Coussemi~l, KM A~fson,  J, Schare~, F. Van de Wed, 
E, Braunwald, ~ the TIMt '/4 Invesr~atots. ~z~ttam and P,~men~ 
HOS~!at. Boston. M& US4 
TO delemtme whe~ lhe ptatelet GPIIb/llla receplor antagonist abommab 
enhances thfombofysts, the TIMI 14 IP.al is ~ patmofs w~th ~ ? 
MI < 12 h ol ~ to fecewe: accelerated full dose IPA versus ReoPro 
(bolus 0.25 mg~g. infusion 0 125 ~,g;kg/n~n . 12 h) atone or with reduced 
doses el 5trept~mase (SK) or tPA~ All palmnts receNe esl~,n (150-325 
rag) and belPann (aPTT 50-70 s), Results to date in me dose lin~ng phase 
(groups of 35 pts) are: 
~ :  IPA ReoPro SK+ReoPro tPA.ReoPro 
ReoPm + * * * ,. 
SK(U, t0% - - 500 750 - - 
tPA (rag) tOO - - 20 35 
TIM.I 3 ffo~ (90 rrvn) 60% 31% 42% 37% 55% 71% 
Ma~or Hemowhage (%) 5 6 6 8 6 0 
Other doses ol lyres to be tested w~th a.~x:tximab incfu(k~ 1.25 MUSK 
and 50 mg tPA. The. oefireum regimen(s) w~!l then be evaluated in a dose 
coof!rmabon phase. 
Concfus~on: In ST I MI. platslet inhibdlon alone with abcix~mab does 
not achieve desirable levels of TIMI 3 flow. However. it has a syner~ic 
effect with markedly [educed doses of thrembolytms, prodacmg flow rates 
as high as tho~e obtained with conventional doses of SK or tPA In the 
regimens tested to date, this apears to be accomplished without an increase 
in bleeding ask, suggesting that abctximab and low dose thmmboly1~cs may 
be an attrachve new approach to repertus=on 
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~8"-~"] Survival Benefit  of Abc ix lmab During Administration 
Early Rescue Angioplasty: Analysis of 387 Patients 
From the GUSTO-Ill Trial 
JM. Miller. EM. Ohman, J.S. Scbltdcrout, R.W. Smallmg, A. Betnu. 
RM Calift. E.J. Topoi. Duke University Medical Center, Durham. NC. USA 
Background and Methods: Abciximab (c7E3) reduces ischemic events after 
high-risk and elective PTCA. but its nsks and benefits during rescue angio- 
plasty are uncertain. We evaluated 387 pts who had PTCA of the IRA -:24 
h after receiving thrombolytic therapy (median 3.5 h). 81 pts received c7E3 
while 306 did not. 
ReSultS: Pts given c7E3 were similar in age and gender, compared with 
the non..cTE3 group. Pts given c7E3 were less likely to have antenor MI 
location (37% vs 52%, p = 0.02), but were more often Killip class III or IV (8% 
vs 2%, p = 0.01). 
Abctximab No abciximab P 
Pro-PTCA TIMI 0-1 40 170) 136 (61%) 
Intractanial b eed 0 2 (07) 
Moderate bleed 13 t16) 45 (15) 
Severe bleeding 3 (3.7) 3 (10) 008 
30-d Mortahty 3 (37) 30 i9.8) 004" 
( ) = % "Adjusted for baseline differences 
Among c7E3 pts, r.PA+ c7E3 had a lower combined endpoint of death, 
MI, stroke (8% vs 21%. p = 0.07) compared with t-PA+ c7E3. 
Conclusion: Selective use of c7E3 in pts undergoing rescue PTCA is 
associated with lower 30 day mortality, with a modest increase in bleeding. 
Future studies should explore the appropriate dose of fibrinolytic, heparin 
end c7E3 to further improve the survival in acute ML 
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84~_ .~ Combined Therapy With $ t~ptok inau  and Inllsgdlin 
E Ronner, HAM van Kestemn, P Zilnen, U Tebbe, P Mott~ek, C Curie, 
E Velte, T~ Lorenz, K Ne,Jn~us, ML  S~moons T~xc~n~t, E',=~m~ 
Un~vers;l~, Rolferdam, Th~ 
Expenmentat =ludtes have sho~n improved ¢t0t lysla t~y com~m~m ol 
thrombolyti¢ th@mpY ar~l IpIatelet GP IIb.lllP, receptor ~kef~ ~ we 
m~se (1,500,000 units) and I~ lm,  a compet~bve II~l!lzt blocker m 
presenting wllh i~ule ~ t  infa~orl, lntegn!m wM a~av, stefe¢l 8s iv 
bolus of 180 ~g~g followed by an m ~  of 0?5, t.33 of ;L0 ~di&gtmm, 
Patients were random~ed to ~ doses or Io placebo (r~=o 2:1) m an 
~sc-.al~tmg n~nner. 
The ~ghast dose an~ was d~;'ontinued when an ~¢mased 
rate was obs~n~l~ Them were no inlrao~r~a! hemorrhages, and the vast 
m, aionty of t~ng was from ~rtena! pu~tum s~tes, Comnan/angmgrams 
were per fo~ 90 mlnute~ afte¢, i~tiatmn Of s1~inase  and Sludy drug 
tO assess T!MI grade flow. Results from 171 of 18t patmnl~ ra~zeO fs 
del:.cled below: 
Inl~td~n 
Placebo 180~ 75 tSO/1 33 I SO~20 
Patients In) 59 43 42 27 
TIMI flo~ 0-1 (%) 38 22 27 12 
2 (%l 27 25 29 3~ 
3 (%~ 38 53 44 52 
Breedrng n~ne t%) 75 53 29 33 
mild (%) 22 30 31 25 
mod/sev (%) 3 16 40 40 
REIC Transfusion (%) 0 12 12 19 
Comb0ned therapy w~h streptokinase and Integfllin in patients with evolv. 
ing myocardial infarctmn ymlde¢l a modest increase m early (90 minutes) 
TIMI grade 3 flow compared with slreptokinase and placebo However, this 
combna~on was also asso~ated wTth an increase m btee~ng, pamculady 
at the higher doses tested. Combination of full dose streptokinase and the 
higher doses of lnteg~lm used in thrs study should he avoided. Evaluation 
Of other dose regrmens of (other) ff~romOohr~ca and Integnlin is warranted to 
obtain increased mparfusmn rates wdhout increasing the nsk of bteeckng. 
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-~-~ Low Weight Heparin Molecular Versus 
Unfractionated Heparln Following Thrombolysls in 
Myocardial Infarct ion 
SH Baird, SJ. Mc Bnde. TG Trouton, C. Wilson Anfnm Area Hospital, 
An~nm. UI'( 
Backgcound: Optimal adjuvant therapy following thrombolysls for acute my- 
ocardial infarction [AMI) remains an unresolved issue although intravenous 
ur~fractionated hep~rin (UFH) is commonly used. We compared the use of 
low molecular weight heparm (LMWH) w=th UFH following thrombofysts, 
Methods: Three hundred patie~s treated wllh thrombolysis for AMI were 
randomly assigned LMWH as enoxapann (40 mg LV. initially, then 40 mg 8 
hourly subcutaneously, n = 149) or UFH (30,000 units daily by contimmus 
Lv. infusmn, n = 151) for 4 days in conjunction with routine therapy. The 
groups were s~milar in relation to age. sex, peak serum cmatinine kinase, 
thrombolytic agent used and use of beta blockers and aspmn. 
Results: Companson of signifcant cardiac events in the patient groups 
mcewing LMWH or UFH over 3 months follow up was as follows: death from 
cardiac cause occurred in 9 vs. 16 patients (p = 0.15); non fatal reinfarction 
22 vs. 30 patients (p = 0.24): readmiss~on with a diagnosis of cardiac pain 
without infarcbon 7 vs. 9 patients (p = 0.62). Combining these end-points, 38 
patients (26%) in the LMWH group vs. 55 patients (3~'=) in the UFH group 
sustained a cardiac event dunng follow up (p = 0.04). Reinfaretion in the 48 
hours after discontinuation of study drug was significantly less frequent for 
LMWH than UFH (3 vs. 10 patients, p = 0.05). The frequency of clinically 
significant haemorrhage was stm=lar in the two groups 
Conclusion: The use of LMWH renewing thrombotysts =s afe and effectwe, 
significantly reducing further cardfac events. 
